161 related articles for article (PubMed ID: 19542194)
21. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study.
Szulc P; Munoz F; Marchand F; Chapuy MC; Delmas PD
Calcif Tissue Int; 2003 Dec; 73(6):520-30. PubMed ID: 12958693
[TBL] [Abstract][Full Text] [Related]
22. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
23. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
24. Circulating and tissue-derived isoforms of bone alkaline phosphatase in Paget's disease of bone.
Magnusson P; Davie MW; Sharp CA
Scand J Clin Lab Invest; 2010 Apr; 70(2):128-35. PubMed ID: 20175736
[TBL] [Abstract][Full Text] [Related]
25. Effects of vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels.
Nakashima A; Yorioka N; Doi S; Masaki T; Ito T; Harada S
Bone; 2004 Mar; 34(3):579-83. PubMed ID: 15003806
[TBL] [Abstract][Full Text] [Related]
26. Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight.
Viapiana O; Gatti D; Dalle Grave R; Todesco T; Rossini M; Braga V; Idolazzi L; Fracassi E; Adami S
Bone; 2007 Apr; 40(4):1073-7. PubMed ID: 17240212
[TBL] [Abstract][Full Text] [Related]
27. Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis.
Bergman A; Qureshi AR; Haarhaus M; Lindholm B; Barany P; Heimburger O; Stenvinkel P; Anderstam B
J Nephrol; 2017 Apr; 30(2):255-262. PubMed ID: 26994005
[TBL] [Abstract][Full Text] [Related]
28. Persistent idiopathic hyperphosphatasemia from bone alkaline phosphatase in a healthy boy.
Whyte MP; Ma NS; Mumm S; Gottesman GS; McAlister WH; Nenninger AR; Bijanki VN; Ericson KL; Magnusson P
Bone; 2020 Sep; 138():115459. PubMed ID: 32474245
[TBL] [Abstract][Full Text] [Related]
29. Bone alkaline phosphatase: An important biomarker in chronic kidney disease - mineral and bone disorder.
Nizet A; Cavalier E; Stenvinkel P; Haarhaus M; Magnusson P
Clin Chim Acta; 2020 Feb; 501():198-206. PubMed ID: 31734146
[TBL] [Abstract][Full Text] [Related]
30. Glycosylation differences contribute to distinct catalytic properties among bone alkaline phosphatase isoforms.
Halling Linder C; Narisawa S; Millán JL; Magnusson P
Bone; 2009 Nov; 45(5):987-93. PubMed ID: 19631305
[TBL] [Abstract][Full Text] [Related]
31. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
[TBL] [Abstract][Full Text] [Related]
32. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
[TBL] [Abstract][Full Text] [Related]
33. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
[TBL] [Abstract][Full Text] [Related]
34. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
35. Age-independent association between arterial and bone remodeling in mild-to-moderate chronic kidney disease.
Briet M; Maruani G; Collin C; Bozec E; Gauci C; Boutouyrie P; Houillier P; Laurent S; Froissart M
Nephrol Dial Transplant; 2010 Jan; 25(1):191-7. PubMed ID: 19654229
[TBL] [Abstract][Full Text] [Related]
36. Associations of Changes in Bone Turnover Markers with Change in Bone Mineral Density in Kidney Transplant Patients.
Jørgensen HS; Claes K; Smout D; Naesens M; Kuypers D; D'Haese P; Cavalier E; Evenepoel P
Clin J Am Soc Nephrol; 2024 Apr; 19(4):483-493. PubMed ID: 38030558
[TBL] [Abstract][Full Text] [Related]
37. Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents.
Magnusson P; Häger A; Larsson L
Pediatr Res; 1995 Dec; 38(6):955-61. PubMed ID: 8618800
[TBL] [Abstract][Full Text] [Related]
38. News on biomarkers in CKD-MBD.
Mazzaferro S; Tartaglione L; Rotondi S; Bover J; Goldsmith D; Pasquali M
Semin Nephrol; 2014 Nov; 34(6):598-611. PubMed ID: 25498379
[TBL] [Abstract][Full Text] [Related]
39. Utility of serum tartrate-resistant acid phosphatase isoform 5b, bone alkaline phosphatase and osteocalcin in osteoporotic fractures in Chinese patients.
Cao Y; Liu X; Xu H
Clin Lab; 2012; 58(7-8):845-50. PubMed ID: 22997989
[TBL] [Abstract][Full Text] [Related]
40. Relevance of parathyroid hormone (PTH), vitamin 25(OH)D3, calcitonin (CT), bone metabolic markers, and bone mass density (BMD) in 860 female cases.
Zhang M; Li Y; Ma Q; Mao W; Gao Y; Liu Y; Liang B
Clin Exp Obstet Gynecol; 2015; 42(2):129-32. PubMed ID: 26054103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
